Company intelligence / Profile preview

Sydnexis Inc.

San Diego/Del Mar, California, United Statessydnexis.com ↗

Ownership: Private
Development stage: Phase 3

Overview

Sydnexis has completed a three-year Phase 3 clinical trial (STAR Study) evaluating its proprietary low-dose atropine formulation (SYD-101) to slow the progression of pediatric myopia. The FDA has accepted their NDA with a PDUFA target action date of October 23, 2025[5].

Therapeutic areas: Ophthalmology
Modalities: Small molecules (low-dose atropine formulation)
Industry: Biotech

Drug pipeline

1 asset

SYD-101

Beyond the preview

Go deeper on Sydnexis Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sydnexis Inc..

Explore the full profile